Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization

Recurrent Hepatocellular Carcinoma Clinical Trial

Official title:
International Randomized Study of Transarterial Chemoembolization (TACE) Versus Stereotactic Body Radiotherapy (SBRT) / Stereotactic Ablative Radiotherapy (SABR) for Residual or Recurrent Hepatocellular Carcinoma After Initial TACE

Status Terminated

Clinical Trial Summary

This randomized phase III trial studies how well transarterial chemoembolization (TACE) works compared to stereotactic body radiation therapy (SBRT) or stereotactic ablative radiation therapy (SABR) in patients with liver cancer that remain after attempts to remove the cancer have been made (residual) or has come back (recurrent). TACE is a minimally invasive, image-guided treatment procedure that uses a catheter to deliver both chemotherapy medication and embolization materials into the blood vessels that lead to the tumors. SBRT or SABR may be able to send radiation directly to the tumor and cause less damage to normal liver tissue. It is not yet known whether TACE is more effective than SBRT or SABR in treating patients with persistent or recurrent liver cancer who have undergone initial TACE.

Clinical Trial Description

PRIMARY OBJECTIVES: I. To determine the freedom from local progression (FFLP) of TACE versus (vs) SABR in patients with persistent hepatocellular carcinoma (HCC) after TACE. SECONDARY OBJECTIVES: I. To determine the progression-free survival (PFS) of TACE vs SABR in patients with persistent HCC after initial TACE. II. To determine the overall survival (OS) of TACE vs SABR for persistent HCC. III. To determine the toxicities associated with TACE or SABR for persistent HCC. OUTLINE: Patients are randomized to 1 of 2 treatment arms. Arm I: Patients undergo TACE. ARM II: Beginning within 2 weeks of the radiation set-up scan and within 4 weeks of fiducial seed implantation (if applicable), patients undergo image guided SBRT 3 fractions within 1 week or 5 fractions within 2 weeks. After completion of study treatment, patients are followed up for 1-2 weeks, 1, 3, 6, 12, and 18 months, and every 6 months up to 3 years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02762266
Study type	Interventional
Source	Stanford University
Contact
Status	Terminated
Phase	Phase 3
Start date	February 27, 2016
Completion date	December 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04851119` - Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT02143401` - Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors	Phase 1
Active, not recruiting	`NCT04514484` - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	Phase 1
Completed	`NCT02728219` - Comparison of Treatment of Recurrent HCC With Repeat Hepatectomy,and TACE With AFP Conversion	N/A
Active, not recruiting	`NCT02867592` - Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors	Phase 2
Active, not recruiting	`NCT04677088` - TCR-Redirected T Cell Treatment in Patients With Recurrent HBV-related Hepatocellular Carcinoma Post Liver Transplantation	Phase 1
Completed	`NCT01522820` - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors	Phase 1
Recruiting	`NCT03609268` - Stereotactic Body Radiotherapy and Microwave Ablation for Recurrent Small Hepatocellular Carcinoma	N/A
Completed	`NCT02613156` - Efficacy Analysis of Complete Laparoscopic Resection of Recurrent Hepatocellular Carcinoma	N/A
Recruiting	`NCT02719782` - A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver Transplantation	Phase 1
Recruiting	`NCT04800497` - The Role Of Circulating Tumor Cells As Markers Of Advanced Disease And Prognosis In HCC
Active, not recruiting	`NCT03257761` - Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer	Phase 1
Active, not recruiting	`NCT03655002` - IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer	Phase 1
Withdrawn	`NCT01318200` - Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)	Phase 3
Completed	`NCT01015833` - Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer	Phase 3
Recruiting	`NCT04663035` - Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC	Phase 2
Withdrawn	`NCT05327738` - Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma	Phase 2
Recruiting	`NCT04615143` - Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC	Phase 2
Active, not recruiting	`NCT04805788` - Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer	Phase 2
Withdrawn	`NCT03634683` - A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation	Phase 1/Phase 2